Dr. Alan Tyler Cease, MD

Dr. Cease practices at UAB St. Vincent’s Birmingham in Birmingham, Alabama, part of University of Alabama at Birmingham.

Dr. Cease's NPI, 1588929855, was assigned on July 11, 2012. Dr. Cease holds Alabama license MD.34134.

Dr. Cease's primary practice is UAB St. Vincent’s Birmingham, at 810 St Vincent's Drive, Birmingham, AL 35205 in Jefferson County. The practice phone is (205) 939-7000.

Dr. Cease's primary practice is UAB St. Vincent’s Birmingham in Birmingham, Alabama, part of University of Alabama at Birmingham. Dr. Cease is also affiliated with UAB Hospital. The medical group on file is UAB Medicine. Dmand AI also links Dr. Cease to 2 more hospitals and 9 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cease practices, 4 sites in all. Vendor and product names are available with a free account.

Emergency medicine is Dr. Cease's primary specialty in the NPI Registry, under taxonomy code 207P00000X. Dmand AI has Dr. Cease's licenses on file in 2 states: Alabama and Mississippi.

CMS data shows 883 Medicare services from Dr. Cease across 6 procedure codes in 2024, for 742 Medicare patients. Medicare paid $96,772 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 742 Medicare patients who saw Dr. Cease in 2024. The largest group is 65 to 74, with 247 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 30% are also on Medicaid. Their average risk score is 2.36, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cease's median patient age at 63, with 59% women.

In 2024, Dr. Cease wrote 479 Medicare Part D claims for 269 patients. 96% of them were for generic drugs. CMS names the drug for 309 of them, across 12 drugs with 11 or more claims each, at $1,727 in total drug cost. In 2023, CMS named 272 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 59 out of 100 for Dr. Cease for performance year 2024, reported as part of a group. Dr. Cease accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 1 paper to Dr. Cease. Dr. Cease's most frequent co-author is Kathy W. Monroe, MD.

CMS Open Payments shows 22 general payments to Dr. Cease from 8 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $551.